Shares of Sarepta (SRPT -1.06%) were trading down 5%, after the company released its 62-week look at its Duchenne muscular dystrophy drug Eteplirsen. The company's 48-week look at the drug produced results that indicated the drug may revolutionize the way we treat the disease, as it not only slowed DMD's progression, it actually lengthened the distance patients were able to walk. The 62-week results were also good, but, perhaps, the market was expecting a miracle after what it saw at the 48-week mark. Sarepta stock jumped up 26% in November for a colossal 550% for the year.